Statements (32)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
opioid
fentanyl analogue |
| gptkbp:antidote |
gptkb:naloxone
|
| gptkbp:CASNumber |
79704-90-4
|
| gptkbp:chemicalFormula |
C23H30N2O
|
| gptkbp:controlled_under |
gptkb:United_Nations_Convention_on_Psychotropic_Substances
|
| gptkbp:developedBy |
gptkb:Russia
|
| gptkbp:discoveredBy |
1976
|
| gptkbp:excretion |
gptkb:kidney
|
| gptkbp:first_illicit_use |
late 1970s
|
| https://www.w3.org/2000/01/rdf-schema#label |
alpha-methylfentanyl
|
| gptkbp:IUPACName |
N-phenyl-N-[1-(1-phenylpropan-2-yl)piperidin-4-yl]propanamide
|
| gptkbp:legalStatus |
Schedule I controlled substance
|
| gptkbp:metabolism |
liver
|
| gptkbp:molecularWeight |
350.5 g/mol
|
| gptkbp:PubChem_CID |
62713
|
| gptkbp:relatedTo |
fentanyl
3-methylfentanyl |
| gptkbp:riskFactor |
high potential for abuse
fatal overdose |
| gptkbp:routeOfAdministration |
oral
inhalation intravenous |
| gptkbp:sideEffect |
addiction
overdose respiratory depression euphoria analgesia |
| gptkbp:UNII |
6Q1V1Y1Y1E
|
| gptkbp:usedFor |
recreational drug
|
| gptkbp:bfsParent |
gptkb:China_White
|
| gptkbp:bfsLayer |
6
|